Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS
Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Sponsor: Brainstorm-Cell Therapeutics
Listed as NCT04681118, this observational or N/A phase trial focuses on Amyotrophic Lateral Sclerosis and remains ongoing. Sponsored by Brainstorm-Cell Therapeutics, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
May 2024 — Jul 2024 [monthly]
No Longer Available
-
Sep 2022 — May 2024 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Apr 2022 — Sep 2022 [monthly]
Available
▶ Show 1 earlier version
-
Jan 2021 — Apr 2022 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brainstorm-Cell Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .